Drug Patent & Exclusivity Expiration Report - Week of March 24 2025 This week, there are 10 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - NALPROPION PHARMACEUTICALS LLC's CONTRAVE, containing active ingredient BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - WYETH PHARMACEUTICALS LLC's PROTONIX, containing active ingredient PANTOPRAZOLE SODIUM - PURDUE PHARMA LP's OXYCONTIN, containing active ingredient OXYCODONE HYDROCHLORIDE - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - BRISTOL MYERS SQUIBB CO's ZEPOSIA, containing active ingredient OZANIMOD HYDROCHLORIDE - VERITY PHARMACEUTICALS INC's TLANDO, containing active ingredient TESTOSTERONE UNDECANOATE - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - VIIV HEALTHCARE CO's VOCABRIA, containing active ingredient CABOTEGRAVIR SODIUM
2025 03-24 Drug Patent & Exclusivity Expiration Report - Week of March 17 2025 This week, there are 9 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - SANTARUS INC's GLUMETZA, containing active ingredient METFORMIN HYDROCHLORIDE - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - INCYTE CORP's JAKAFI, containing active ingredient RUXOLITINIB PHOSPHATE - FRESENIUS KABI USA LLC's SMOFLIPID 20%, containing active ingredient FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - NOVEN PHARMACEUTICALS INC's XELSTRYM, containing active ingredient DEXTROAMPHETAMINE - NOBELPHARMA CO LTD's HYFTOR, containing active ingredient SIROLIMUS - NOVARTIS PHARMACEUTICALS CORP's LOCAMETZ, containing active ingredient GALLIUM GA-68 GOZETOTIDE
2025 03-17 Drug Patent & Exclusivity Expiration Report - Week of March 10 2025 This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib
2025 03-10 Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025 This week, there are 12 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - VIFOR PHARMA INC's VELTASSA, containing active ingredient PATIROMER SORBITEX CALCIUM - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN
2025 02-24 Drug Patent & Exclusivity Expiration Report - Week of Feb 17 2025 This week, there are 7 drugs in the patent and exclusivity list. They are: - DURYSTA by AbbVie Inc, containing active ingredient Bimatoprost - IXEMPRA KIT by R-Pharm US LLC, containing active ingredient Ixabepilone - XIFAXAN by Salix Pharmaceuticals Inc, containing active ingredient Rifaximin - DIFFERIN by Galderma Laboratories LP, containing active ingredient Adapalene - NEXLIZET by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid; Ezetimibe - NEXLETOL by Esperion Therapeutics Inc, containing active ingredient Bempedoic Acid - XARELTO by Janssen Pharmaceuticals Inc, containing active ingredient Rivaroxaban
2025 02-17 Drug Patent & Exclusivity Expiration Report - Week of Feb 10 2025 This week, there are 6 drugs in the patent and exclusivity list. They are: - Tudorza Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide - Duaklir Pressair by Covis Pharma GMBH, containing active ingredient Aclidinium Bromide and Formoterol Fumarate - Scenesse by Clinuvel Inc, containing active ingredient Afamelanotide - Hysingla ER by Purdue Pharma LP, containing active ingredient Hydrocodone Bitartrate - Izervay by Astellas Pharma US Inc, containing active ingredient Avacincaptad Pegol Sodium - Symdeko by Vertex Pharmaceuticals Inc, containing active ingredient Ivacaftor and Tezacaftor
2025 02-10 Drug Patent & Exclusivity Expiration Report - Week of Feb 03 2025 This week, there are 4 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZOLINZA, containing active ingredient VORINOSTAT
2025 02-03 Drug Patent & Exclusivity Expiration Report - Week of Jan 27 2025 This week, there are 10 drugs in the patent and exclusivity list. They are: - Myfembree by Sumitomo Pharma Switzerland, containing active ingredient Estradiol, Norethindrone Acetate, and Relugolix - Orgovyx by Sumitomo Pharma Switzerland, containing active ingredient Relugolix - Nulibry by Sentynl Therapeutics, containing active ingredient Fosdenopterin Hydrobromide - Delstrigo by Merck Sharp and Dohme, containing active ingredient Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate - Pifeltro by Merck Sharp and Dohme, containing active ingredient Doravirine - Geodon by Viatris Specialty, containing active ingredient Ziprasidone Hydrochloride - Reyvow by Eli Lilly, containing active ingredient Lasmiditan Succinate - Cabenuva Kit by ViiV Healthcare, containing active ingredient Cabotegravir and Rilpivirine - Vocabria by ViiV Healthcare, containing active ingredient Cabotegravir Sodium - Imbruvica by Pharmacyclics, containing active ingredient Ibrutinib
2025 01-27 Drug Patent & Exclusivity Expiration Report - Week of Jan 20 2025 This week, there are 7 drugs in the patent and exclusivity list. They are: - CUMBERLAND PHARMACEUTICALS INC's SANCUSO, containing active ingredient GRANISETRON - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - EPIZYME INC's TAZVERIK, containing active ingredient TAZEMETOSTAT HYDROBROMIDE - EVOFEM INC's SOLOSEC, containing active ingredient SECNIDAZOLE - ADVANCED ACCELERATOR APPLICATIONS USA INC's LUTATHERA, containing active ingredient LUTETIUM LU 177 DOTATATE
2025 01-20